Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population.

导出 LinkOut

翻译打印收藏纠错

作者： Lauren C,Shapiro ^[1] ; Jennat,Mustafa ^[1] ; Amanda,Lombardo ^[1] ; Fariha,Khatun ^[1] ; Felisha,Joseph ^[1] ; Kailyn,Gillick ^[1] ; Anjali,Naik ^[1] ; Richard,Elkind ^[1] ; Michelly,Abreu ^[1] ; Karen,Fehn ^[1] ; Alyssa,de Castro ^[2] ; Kith,Pradhan ^[1] ; Donika,Binakaj ^[1] ; Randin,Nelson ^[3] ; Monika,Paroder ^[3] ; Joan,Uehlinger ^[3] ; Kira,Gritsman ^[1] ; R,Alejandro Sica ^[1] ; Noah,Kornblum ^[1] ; Aditi,Shastri ^[1] ; Ioannis,Mantzaris ^[1] ; Lizamarie,Bachier-Rodriguez ^[1] ; Amit,Verma ^[1] ; Ira,Braunschweig ^[1] ; Mendel,Goldfinger ^[4]

作者单位： Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. ^[1] Department of Pharmacy, Montefiore Medical Center, Bronx, NY, USA. ^[2] Department of Pathology, Montefiore Medical Center, Bronx, NY, USA. ^[3] Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. mgoldfin@montefiore.org. ^[4]

主题词老年人(Aged);抗原, CD19(Antigens, CD19);生物制品(Biological Products);人类(Humans);免疫疗法, 过继(Immunotherapy, Adoptive);淋巴瘤, 大B细胞, 弥漫性(Lymphoma, Large B-Cell, Diffuse)

DOI 10.1038/s41409-021-01280-3

PMID 33846558

发布时间 2021-12-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交